Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Hosted on MSN14d
Novo Nordisk and Valo expand cardiometabolic drug partnershipNovo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop ...
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.
Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback